Precigen (STU:I5X) E10: €-1.23 (As of Mar. 2026)


STU:I5X Precigen Inc STU:I5X
59 GF Score
Price €4.80
GF Value €5.33
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Precigen E10?

Precigen STU:I5X -1.64% 59 E10 is €-1.23 as of Mar. 2026. GuruFocus rates STU:I5X with a GF Score™ of 59/100 and a GF Value™ of €5.33 (Modestly Undervalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Precigen's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.017. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.23 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 17.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Precigen was 32.80% per year. The lowest was 17.20% per year. And the median was 25.00% per year.

As of today (2026-07-07), Precigen's current stock price is €4.80. Precigen's E10 for the quarter that ended in Mar. 2026 was €-1.23. Precigen's Shiller PE Ratio of today is .


Precigen  (STU:I5X) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Precigen E10 Related Terms


Precigen E10 Historical Data

* Premium members only.

The historical data trend for Precigen's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Precigen E10 Chart

Precigen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.15 -2.24 -1.35 -0.88 -1.33

Precigen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.37 -1.22 -1.34 -1.33 -1.23

STU:I5X vs KARD, SLBT, GENB: E10 Comparison

For the Biotechnology subindustry, Precigen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precigen Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precigen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Precigen's Shiller PE Ratio falls into.


STU:I5X
59GF Score
Precigen Inc STU:I5X
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Precigen E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Precigen's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.017/330.2130*330.2130
=-0.017

Current CPI (Mar. 2026) = 330.2130.

Precigen Quarterly Data

per share eps CPI Adj_EPS
201606 -0.374 241.018 -0.512
201609 -0.214 241.428 -0.293
201612 -0.351 241.432 -0.480
201703 -0.243 243.801 -0.329
201706 -0.142 244.955 -0.191
201709 -0.277 246.819 -0.371
201712 -0.194 246.524 -0.260
201803 -0.292 249.554 -0.386
201806 -0.437 251.989 -0.573
201809 -0.377 252.439 -0.493
201812 -2.277 251.233 -2.993
201903 -0.354 254.202 -0.460
201906 -0.221 256.143 -0.285
201909 -0.318 256.759 -0.409
201912 -0.981 256.974 -1.261
202003 -0.317 258.115 -0.406
202006 -0.231 257.797 -0.296
202009 -0.153 260.280 -0.194
202012 -0.189 260.474 -0.240
202103 -0.076 264.877 -0.095
202106 -0.083 271.696 -0.101
202109 -0.128 274.310 -0.154
202112 -0.115 278.802 -0.136
202203 -0.091 287.504 -0.105
202206 -0.085 296.311 -0.095
202209 0.444 296.808 0.494
202212 -0.104 296.797 -0.116
202303 -0.093 301.836 -0.102
202306 -0.074 305.109 -0.080
202309 -0.075 307.789 -0.080
202312 -0.119 306.746 -0.128
202403 -0.092 312.332 -0.097
202406 -0.214 314.175 -0.225
202409 -0.081 315.301 -0.085
202412 -0.057 315.605 -0.060
202503 -0.166 319.799 -0.171
202506 -0.078 322.561 -0.080
202509 -0.903 324.800 -0.918
202512 -0.009 324.054 -0.009
202603 -0.017 330.213 -0.017

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.23 mean?
Precigen (STU:I5X) has a E10 of €-1.23 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Precigen and its competitors.
Is Precigen's E10 too high?
Precigen's current E10 is €-1.23. Overall, Precigen has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Precigen's E10 compare to KARD and SLBT?
Precigen's E10 of €-1.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Precigen and its competitors. Precigen's current E10 is €-1.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precigen stock overvalued right now?
Based on GuruFocus' analysis, Precigen (STU:I5X) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.33, compared to a current price of €4.80 — trading 9.9% below its estimated fair value. The current E10 is €-1.23. Precigen's overall GF Score™ is 59/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Precigen (STU:I5X), the current E10 is €-1.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Precigen (STU:I5X) Overvalued in 2026?

Based on GuruFocus' analysis, Precigen stock appears to be undervalued. The current stock price of €4.80 is trading 9.9% below its estimated GF Value™ of €5.33. GuruFocus considers Precigen to be Modestly Undervalued.

Key valuation signals for STU:I5X:

  • E10: €-1.23
  • GF Value™: €5.33 vs. price of €4.80 (9.9% below fair value)
  • GF Score™: 59/100 with 10 warning signs

No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Precigen Business Description

Other Exchanges PGEN:USA
Address 20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
59GF Score

Get the complete analysis for STU:I5X

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.80
Price
€5.33
GF Value